AIM: To explore the value of fecal lactoferrin in predicting and monitoring the clinical severity of infectious diarrhea. METHODS: Patients with acute infectious diarrhea ranging from 3 mo to 10 years in age were enrolled, and one to three stool samples from each subject were collected. Certain parameters, including white blood cells /differential count, C-reactive protein, fecal mucus, fecal pus cells, duration of fever, vomiting, diarrhea and severity (indicated by Clark and Vesikari scores), were recorded and analyzed. Fecal lactoferrin was determined by enzyme-linked immunosorbent assay and compared in different pathogen and disease activity. Generalized estimating equations (GEE) were also used for analysis. RESULTS: Data included 226 evaluations for 117 individuals across three different time points. Fecal lactoferrin was higher in patients with Salmonella (11.17 μg/g ± 2.73 μg/g) or Campylobacter (10.32 μg/g ± 2.94 μg/g) infections and lower in patients with rotavirus (2.82 μg/g ± 1.27 μg/g) or norovirus (3.16 μg/g ± 1.18 μg/g) infections. Concentrations of fecal lactoferrin were significantly elevated in patients with severe (11.32 μg/g ± 3.29 μg/g) or moderate (3.77 μg/g ± 2.08 μg/g) disease activity compared with subjects with mild (1.51 μg/g ± 1.36 μg/g) disease activity (P < 0.05). GEE analysis suggests that this marker could be used to monitor the severity and course of gastrointestinal infections and may provide information for disease management. CONCLUSION: Fecal lactoferrin increased during bacterial infection and with greater disease severity and may be a good marker for predicting and monitoring intestinal inflammation in children with infectious diarrhea.
AIM: To explore the value of fecal lactoferrin in predicting and monitoring the clinical severity of infectious diarrhea. METHODS:Patients with acute infectious diarrhea ranging from 3 mo to 10 years in age were enrolled, and one to three stool samples from each subject were collected. Certain parameters, including white blood cells /differential count, C-reactive protein, fecal mucus, fecal pus cells, duration of fever, vomiting, diarrhea and severity (indicated by Clark and Vesikari scores), were recorded and analyzed. Fecal lactoferrin was determined by enzyme-linked immunosorbent assay and compared in different pathogen and disease activity. Generalized estimating equations (GEE) were also used for analysis. RESULTS: Data included 226 evaluations for 117 individuals across three different time points. Fecal lactoferrin was higher in patients with Salmonella (11.17 μg/g ± 2.73 μg/g) or Campylobacter (10.32 μg/g ± 2.94 μg/g) infections and lower in patients with rotavirus (2.82 μg/g ± 1.27 μg/g) or norovirus (3.16 μg/g ± 1.18 μg/g) infections. Concentrations of fecal lactoferrin were significantly elevated in patients with severe (11.32 μg/g ± 3.29 μg/g) or moderate (3.77 μg/g ± 2.08 μg/g) disease activity compared with subjects with mild (1.51 μg/g ± 1.36 μg/g) disease activity (P < 0.05). GEE analysis suggests that this marker could be used to monitor the severity and course of gastrointestinal infections and may provide information for disease management. CONCLUSION: Fecal lactoferrin increased during bacterial infection and with greater disease severity and may be a good marker for predicting and monitoring intestinal inflammation in children with infectious diarrhea.
Entities:
Keywords:
Clark scores; Diarrhea; Generalized estimating equations; Lactoferrin; Vesikari scores
Authors: Ivan J Gotham; Debra L Sottolano; Mary E Hennessy; John P Napoli; Gregory Dobkins; Linh H Le; Robert L Burhans; Bruce I Fage Journal: J Public Health Manag Pract Date: 2007 Sep-Oct
Authors: Ryan Rego; Samuel Watson; Mohammad Atique Ul Alam; Syed Asif Abdullah; Mohammad Yunus; Imam Taskin Alam; A S M Homuan Kabir Chowdhury; S M Arefeen Haider; Asg Faruque; Azharul Islam Khan; Timothy Hofer; Paramjit Gill; Mohammad Sirajul Islam; Richard Lilford Journal: EClinicalMedicine Date: 2021-11-20
Authors: Adam M Nelson; Seth T Walk; Stefan Taube; Mami Taniuchi; Eric R Houpt; Christiane E Wobus; Vincent B Young Journal: PLoS One Date: 2012-10-30 Impact factor: 3.240
Authors: Kelly Parsons; Julius Goepp; Bryan Dechairo; Elizabeth Fowler; Nathan Markward; Patrick Hanaway; Teresa McBride; Darryl Landis Journal: Glob Adv Health Med Date: 2014-05